20.06.2012 - Andrew Bulpin took over Merck-Millipore‘s Process Solutions Business Unit. The chemist – who previously served as Head of Global Pharmaceutical Chemicals Solutions Sales – succeeds the retired Jean-Paul Mangeolle.

Bulpin joined Millipore in 2006 as a Vice President for the firm's Upstream Processing Business Unit. In January 2012, he assumed leadership of the company's Services and Solutions Business Department. Bulpin was appointed to his current position following the company's acquisition by Merck.

14.08.2012 Italian IT expert Massimiliano Claps is the new EMEA research director for the Government and Health Insights department, announced the International Data Corporation (IDC).

Claps will lead IDC’s ongoing research programmes for the government and healthcare sectors in Europe, the Middle East, and Africa. He will also be responsible for analysing key trends related to IT strategies and spending in European governments and healthcare provider organisations. 

After graduating in business administration at Milan’s Bocconi University, Claps worked as a junior consultant for the Monitor Group where he advised major multinationals in the food and beverage, construction, media and telecoms, and pharmaceutical industries. His career in the IT sector began with his first stint at the IDC: Between 2002 and 2007 he worked for the EMEA Government and Health Insights business as well as for a year with IDC Canada to fast-track their government research. Max Clap’s latest assignment was to head the government team of one of the world’s leading information technology research and advisory companies, Gartner, Inc. 

07.08.2012 German biotech Wilex AG will change its executive management board. Chief Financial Officer Peter Llewellyn-Davies has to leave the company upon the expiration of his six year contract on September 1st. Jan Schmidt-Brand will take over.

Schmidt-Brandt is currently the Managing Director of Wilex's subsidiary Heidelberg Pharma GmbH. He was the CEO of Heidelberg Pharma AG until the company was acquired by Wilex. From 1997 to 2001, he was Managing Director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH, where his responsibilities included finance and controlling. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department. Schmidt-Brand is a member of the Board of BioDeutschland and Head of the Finance and Tax working group. Llewellyn-Davies will pursue new activities but continues to act as an advisor for the company. He will fully manage and complete the capital measure announced by Wilex on August 3. “Mr Llewellyn-Davies has made important contributions to the development of Wilex since joining the company prior to its IPO in 2006. We would like to thank him very much for his collaboration, which was both constructive and successful, and wish him great success in realizing his objectives”, said Professor Christof Hettich, Chairman of the Supervisory Board.

03.08.2012 Belgian Amakem NV appointed Maarten van Geffen as new head of CMC and Operations in mid-July.

Van Geffen brings nearly 25 years international management experience in pharmaceutical development to Amakem, a kinase platform company focusing on ophthalmology. Previously, he was Director of Product Development at Shire-Movetis NV and responsible for the pharmaceutical development of the GI early and late phase products and was the CMC (Chemistry, Manufacturing & Controls) lead for due diligence of early phase and late phase small and large molecule products. Prior to working at Shire-Movetis NV, van Geffen held several positions as Director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation.

01.08.2012 Antibody drug-conjugates specialist ADC Therapeutics Sarl has named the former Genmab Vice President Dr Patrick van Berkel as its Senior VP Research & Development.

Van Berkel brings in more than 20 years of experience in the biotech industry, in particular in developing antibody-based drugs. He served with Genmab for more than nine years in different divisions. Prior to Genmab, Dr van Berkel worked for both Crucell and Pharming Technologies. He authors nine antibody patents and has published more than 30 scientific papers during his industry career. Van Berkel predicts an „explosion in ADC therapies  in the coming decade“.

12.07.2012 In June, French Trophos SA appointed Christine Placet as its chief executive officer. She becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos, to bring the company's ongoing programmess to a successful conclusion and to seek strategic partnerships for its advanced clinical development drug candidates.

 From 2004, Placet was CFO of the clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. She has over 25 years' experience in a variety of areas of finance and business management. Prior to joining Trophos, she was CFO in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young. She has a graduate diploma in financial accounting (DESCF) and a business school diploma from Sup de Co Marseille (DESCAF). Damian Marron, previously CEO, has moved to the biopharmaceutical Company Cytheris SA.

18.07.2012 Ark Therapeutics Group (London) has appointed Dr David Venables as its new CEO from the beginning of August.

Since joining the Board in April of this year, he has focused on the development of Ark's viral development and manufacturing capabilities based in Kuopio, Finland. Martyn Williams, who joined the Company in October 1998 as Finance Director and became CEO in mid 2010, will hand over to Venables and leave the Company at the End of July.

25.07.2012 Oslo-based DiaGenic ASA will have a new CEO in September: Paul de Potocki will succeed Henrik Lund, who has led the development of DiaGenic on an interim basis since April 2012.

Before de Potocki moved to DiaGenic, he was CEO of Aerocrine AB, a Swedish medical device and diagnostic company. Prior to joining Aerocrine, he served as Senior Vice President, Commercial and Strategic Development at Biovitrum AB. He has also served as Executive Vice President, Strategic Marketing at the German company Fresenius Kabi, as well as Divisional Vice President, Global Sales and Strategic Marketing with Pharmacia. Before this, he held various international commercial management positions within the Unilever group. Henrik Lund will resume his former position as chairman of DiaGenic.

02.07.2012 Dr. Christian Patermann, the mastermind behind the EU's bioeconomy strategy, has been honoured by the Accademia dei Georgofili in Florence. In a ceremony in the Uffizi at the end of April, Patermann was appointed as a member of the the first public association in Europe dedicated to agrarian studies.

As Programme Director Biotechnology, Agriculture and Food at DG Research of the European Commission, Patermann drafted the EU's knowledge-based bioeconomy plans.

05.07.2012 Swedish Microbiology specialist Medivir AB has appointed Henric Juserius to head the company's commercial activities. The former Commercial Director (Nordic region) of Actelion Pharmaceuticals will have overall responsibility for the firm's marketing and sales.

His main task will be to prepare the commercial launch of Medivir's Phase III product TMC435, which is being co-developed with Janssen Pharma-ceuticals for hepatitis C. 

09.07.2012 InDex Pharmaceuticals (Stockholm) has added Stig Løkke Pedersen to its board. The former VP Commercial Operations at H. Lundbeck A/S brings in 25 years of leadership experience and networking in the biotech and pharmaceutical industries.

Pedersen joined Lundbeck in 1992 as CBO, and was selected to join its corporate senior management in 1998. There he served as Executive Vice President from 2003-2011. Pedersen is a partner at Executive Capital A/S and also serves as the Chairman of the Board of Directors at Chemo-metec A/S and Nuevolution A/S.

Vorherige Seite4/6Nächste Seite


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%


  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%


  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%


  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%


  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%


  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015

Current issue

All issues